IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines
IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines is a paper indexed in ScholarIQ from OpenAlex.
How many citations does IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines have?
IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines has 92 citations in the OpenAlex counts ScholarIQ stores.
When was IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines published?
IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines has 2022 year in the ScholarIQ index.
What is the open-access status of IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines?
IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines has gold oa status in the ScholarIQ index.
What is the DOI of IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines?
The DOI for IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines is on the source record.
What is the PMID of IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines?
The PMID for IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines is on the source record.
What is the OpenAlex record for IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines?
The OpenAlex for IL12 immune therapy clinical trial review: Novel strategies for avoiding CRS-associated cytokines is on the source record.